VTv Therapeutics Plans $80 Million Private Placement to Fund Type 1 Diabetes Therapy

vTv Therapeutics Inc. has secured approximately $80 million through a private placement in public equity (PIPE) financing with leading healthcare institutional investors and the T1D Fund to advance the development of cadisegliatin, a potential first-in-class oral adjunctive therapy for type 1 diabetes. The financing includes the sale of Class A shares and pre-funded warrants, with accompanying warrants exercisable at $22.71 per share, and is expected to close around September 3, 2025. The proceeds will support the ongoing CATT1 Phase 3 clinical trial, which aims to reduce hypoglycemic events and improve glycemic control in people living with type 1 diabetes. Topline data from the CATT1 trial is anticipated in the second half of 2026, potentially paving the way for regulatory submissions. This investment reflects strong confidence from both existing and new investors, including Samsara BioCapital, Trails Edge Capital Partners, and Invus, in vTv's innovative approach to diabetes treatment. The involvement of the T1D Fund further underscores the therapeutic promise of cadisegliatin for diabetic patients.